Zenas BioPharma is a cross-border biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and throughout the world. The company has a deep pipeline of innovative autoimmune therapeutics and is rapidly advancing seven pipeline programs, including three with worldwide rights. Zenas aims to transform the lives of patients living with autoimmune diseases.

Zenas BioPharma

The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the NASDAQ Biotechnology IndexÂ®.
 The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund&#39;s investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

ProShares UltraPro Short Nasdaq Biotechnology

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based therapies for patients around the world. Zenas is rapidly advancing a deep portfolio of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com.

ZBIO

COM:ZENASBIO

Zenas BioPharma

Last Close

14.50

20/11 21:00

Market Cap

2.50M

Beta: -

Volume Today

418.91K

Avg: -

locale

market

industry

website

crunchbase

linkedin

ipo date

peer of

investor of

competitor of

Metrics